BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Gilead Braces For 114 Job Cuts at Former Immunomedics Facility

  Gilead Sciences is letting go of 114 employees following an underwhelming response to the results reaped so far from its $21 billion acquisition of Immunomedics in 2020.

  March 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Cybercrime Explodes as Pharma Financial Fraud Challenges Counterfeiting

  Financial fraud committed by supposed online pharmacies may be as big a threat to society as counterfeit medicines.

  March 10, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Business

  Moderna CEO’s Salary Spikes while the Median Employee’s Falls

  Bancel reaped the rewards of SpikeVax’s success, but the Boston Business Journal noted that annual compensation for Moderna’s median employee plunged 16%.

  March 10, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Morningside Launches Inflammatory-focused Adiso, Scenic Scores $31M for Rare Diseases

  Morningside Ventures launched a new biotech company called Adiso Therapeutics, and thriving startup Scenic Biotech scooped up €28 million ($31 million) in funding.

  March 10, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Study: Programmed Death Ligand 1 (PD-L1) may have Application in Obesity Treatment

  Researchers saw that programmed death ligand 1 on dendritic cells could control adaptive immune responses within adipose tissues to limit diet-induced obesity.

  March 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  Clinical Development Updates from Intellia, Denali, Janssen, Inomagen

  Denali initiates dosing in Phase I/II frontotemporal dementia study. Intellia snags Orphan Drug Designation for experimental T cell receptor (TCR)-T cell therapy, NTLA-5001 in AML.

  March 10, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Tiziana’s Experimental Therapy Shows Promising Results for Multiple Sclerosis Patient

  At the Brigham and Women’s Hospital, a male patient with Secondary Progressive Multiple Sclerosis serves as a beacon of hope for those afflicted with the same neurodegenerative disease.

  March 10, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano M.S.
• 

  Report: Global Psoriatic Arthritis Market Could Exceed $13B by 2026

  The Business Research Company (TBRC), a market research and intelligence firm, released a promising analysis of the global psoriatic arthritis treatment market.

  March 10, 2022

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Business

  Three Biopharma Companies to Settle into New Breakthrough Properties Home

  On Wednesday, Breakthrough Properties announced the launch of StudioLabs, a turnkey, flexible lab and office solution that has been developed for hyper-growth life sciences companies.

  March 10, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Venatorx Scores Victory over AMR in Phase III UTI Study

  Venatorx Pharmaceuticals shared that its Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.

  March 10, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN